Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Hepatocellular 36Carcinoma, Non-Small-Cell Lung 29Triple Negative Breast Neoplasms 23Nasopharyngeal Carcinoma 23Stomach Neoplasms 21Esophageal Squamous Cell Carcinoma 19Esophageal Neoplasms 19Breast Neoplasms 18Squamous Cell Carcinoma of Head and Neck 14Colorectal Neoplasms 12Uterine Cervical Neoplasms 11Sarcoma 10Pancreatic Neoplasms 9Lung Neoplasms 9Recurrence 7Neoplasm Metastasis 7Melanoma 6Hodgkin Disease 6Cholangiocarcinoma 6Liver Neoplasms 5Biliary Tract Neoplasms 5Small Cell Lung Carcinoma 4Osteosarcoma 4Neoplasms 4Advanced Solid Tumor 4Advanced Gastric Cancer 4Solid Tumor 3Respiratory Tract Diseases 3Rectal Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3

Interventions

Cisplatin 7Radiotherapy 3Paclitaxel 3Carboplatin 3Brachytherapy 2zimberelimab 1piperine 1pembrolizumab 1durvalumab 1camrelizumab 1atezolizumab 1Sodium Chloride 1Neoadjuvant Therapy 1Gemcitabine 1Drug Therapy 1Curcumin 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Locally Advanced Cervical Cancer × camrelizumab × Clear all
NCT04884906 2021-05-13

Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
40 enrolled
Gynecologic

Locally Advanced Cervical Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡